Travere Therapeutics price target lowered to $30 from $32, but positive outlook on drug launch.

From Yahoo Finance: 2025-04-12 10:20:00

Scotiabank analyst Greg Harrison lowered Travere Therapeutics’ price target to $30 from $32 but maintains an Outperform rating. The company shared updated data for Filspari in IgA nephropathy and focal segmental glomerulosclerosis, highlighting the drug’s strong clinical profile. Despite potential competition, Filspari’s launch is expected to continue upward due to its unique mechanism and broader label.



Read more at Yahoo Finance: Travere Therapeutics price target lowered to $30 from $32 at Scotiabank